Increased incidence of transformation and myelodysplasia/acute leukemia in patients with Waldenström macroglobulinemia treated with nucleoside analogs. - Wikidata - awgldk - TriplyDB

Increased incidence of transformation and myelodysplasia/acute leukemia in patients with Waldenström macroglobulinemia treated with nucleoside analogs.

Increased incidence of transformation and myelodysplasia/acute leukemia in patients with Waldenström macroglobulinemia treated with nucleoside analogs.

http://www.wikidata.org/entity/Q43651033

about

Diagnosis and management of Waldenström macroglobulinemia: Mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelines Prognostic value of the International Scoring System and response in patients with advanced Waldenstrom macroglobulinemia Therapy-related myeloid neoplasms: pathobiology and clinical characteristics Long-term outcomes to fludarabine and rituximab in Waldenström macroglobulinemia Waldenström macroglobulinemia: 2011 update on diagnosis, risk stratification, and management.Waldenström macroglobulinemia: 2012 update on diagnosis, risk stratification, and management.Waldenström macroglobulinemia: 2013 update on diagnosis, risk stratification, and management.Waldenström macroglobulinemia: 2015 update on diagnosis, risk stratification, and management.A rare case of acute lymphoblastic leukemia in a patient with light chain (AL) amyloidosis treated with lenalidomide.Treatment recommendations for patients with Waldenström macroglobulinemia (WM) and related disorders: IWWM-7 consensus Fludarabine in Waldenstrom's macroglobulinemia.Primary therapy of Waldenström macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180.Therapy-Related Myeloid Neoplasms in Chronic Lymphocytic Leukemia and Waldenstrom's Macroglobulinemia New Therapeutic Approaches for Waldenstrom Macroglobulinemia Waldenström macroglobulinemia with extramedullary involvement at initial diagnosis portends a poorer prognosis Novel agents in Waldenstrom Macroglobulinemia.Radiotherapy- and chemotherapy-induced myelodysplasia syndrome: a nationwide population-based nested case-control study.Waldenstrom's macroglobulinemia associated with Hodgkin's lymphoma: a case report How to manage Waldenstrom's macroglobulinemia.A phase 2 study of concurrent fludarabine and rituximab for the treatment of marginal zone lymphomas.Recommendations for the diagnosis and initial evaluation of patients with Waldenström Macroglobulinaemia: A Task Force from the 8th International Workshop on Waldenström Macroglobulinaemia.Novel treatment regimens for Waldenström's macroglobulinemia.Stem cell transplant for Waldenström macroglobulinemia: an underutilized technique.Risk stratification in Waldenström macroglobulinemia.Molecular pathogenesis of Waldenstrom's macroglobulinemia.What's all the fuss about? facts and figures about bone marrow failure and conditions.Aetiology, genetics and prevention of secondary neoplasms in adult cancer survivors.Waldenström macroglobulinaemia: the key questions.Waldenström macroglobulinemia: from biology to treatment.Current and future therapeutic approach for Waldenström's macroglobulinemia.A focused review of hematopoietic neoplasms occurring in the therapy-related setting.Systematic review of the recent evidence for the efficacy and safety of chlorambucil in the treatment of B-cell malignancies.Dexamethasone, rituximab and cyclophosphamide for relapsed and/or refractory and treatment-naïve patients with Waldenstrom macroglobulinemia.Rare transformation to double hit lymphoma in Waldenstrom's macroglobulinemia.Transformed Waldenström macroglobulinaemia: clinical presentation and outcome. A multi-institutional retrospective study of 77 cases from the French Innovative Leukemia Organization (FILO).Diagnosis and Management of Waldenström Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines 2016.Secondary malignancies in patients with multiple myeloma, Waldenström macroglobulinemia and monoclonal gammopathy of undetermined significance.Waldenstrom Macroglobulinemia: Genomic Aberrations and Treatment.Lenalidomide is safe and active in Waldenström macroglobulinemia.Histological transformation to diffuse large B-cell lymphoma in patients with Waldenström macroglobulinemia.

P2860

Q28290236-A900D8A4-0852-4661-9FB7-166A61E33624 Q28307039-2A45588D-B7FF-4539-B592-E3D1F4636B1D Q28386366-EFF8B84C-C926-4D74-9689-7F1691BFB3CC Q33382030-F0FA9EBA-8303-46CD-A2DA-13E9DC41C1F9 Q33395066-4A6AA41B-2A3F-49F8-AB99-ACDBD7B43CBB Q33400780-D3C258C0-1DC9-4CCD-879A-DCF848D885F6 Q33408517-6A031CCF-7B89-49AD-B472-13124ED4D1AE Q33421444-0CBBD45F-DE1E-4DAF-A67F-2898C4DE5056 Q33802749-7D361DEE-3B48-4E55-9B19-DD556F6339F7 Q34106817-3967A49E-AEB4-417A-913F-43CF3148323E Q34351916-F3C82AC6-4725-4523-8303-7816BBE0B76C Q34608608-86D2C54E-8DBC-452B-AA26-8CECD0F8C2A1 Q35153656-E8A90477-4710-4C72-B0AB-1D45D7C46C54 Q35176177-4B07B82A-5DE3-48CE-A5D6-0A911A1E0248 Q35806665-2CD38548-8D5D-4229-9747-7CD1F96C6B52 Q36117791-A1EFC40C-E9AB-47CE-9A4E-36F26376952A Q36153838-0814FD7C-8456-476D-AB37-484E2F50B33F Q36325566-59D6A262-EDB9-4685-80DC-228604EC2916 Q36764811-E50D9E07-72CE-44AC-A6BE-E3E6641829E0 Q37364653-314BEE27-B198-4024-BC83-05AA19A7F489 Q37499211-AA15C27E-AE1E-4B09-A9C2-DBD3C45F6BB3 Q37810101-3B66D66F-4FFA-48EE-872F-52A65379160D Q37923308-0E54F9F6-3987-4DFD-A2E8-95FEF06C1BC9 Q37999886-B84F5ADC-BA49-4963-9879-74DBEE333AAE Q38024773-F749512C-6F39-4A1B-A726-2495153691A4 Q38039381-BFA499B6-41A4-44B9-996A-C1F7B3AF7BFA Q38093037-596858E7-F24D-4885-A3E9-961D0CA31AB6 Q38104808-15036038-73CC-453F-8344-0E20A8498A5D Q38176969-2E0F92B3-D6F2-4DA9-9CD0-9153203EC57D Q38206820-D5E5E56B-54F9-466F-B6E9-49AD0AB6016C Q38239675-A8B1CC12-A98C-4FB9-91D4-1D583F58D706 Q38574045-0C28EED9-8A93-499A-9E3C-F69C7DBEE8E0 Q38635212-7B1212DE-965F-4B09-B718-A6DBB455622A Q38644775-50D38505-9AC1-4057-9799-4A50C52BBD55 Q38645082-ED8753CE-5924-4853-9C0B-CC3C7F3A8FD3 Q38774535-A5893F22-E47F-455B-8BC6-607A7BD6E164 Q38933428-FD8A06F0-27B8-4407-9486-C3FBF113BD6E Q38970612-D52E5A84-DB5A-492E-9904-6280650F2EC2 Q38973119-9602A086-72C3-4703-B802-69D771FCE4D0 Q40651796-2DC49BB2-C238-4074-BE0F-7557D1FAB65E

P2860

Increased incidence of transformation and myelodysplasia/acute leukemia in patients with Waldenström macroglobulinemia treated with nucleoside analogs.

http://www.wikidata.org/entity/Q43651033

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年学术文章

@wuu

2008年学术文章

@zh

2008年学术文章

@zh-cn

2008年学术文章

@zh-hans

2008年学术文章

@zh-my

2008年学术文章

@zh-sg

2008年學術文章

@yue

2008年學術文章

@zh-hant

name

Increased incidence of transfo ...... eated with nucleoside analogs.

@en

Increased incidence of transfo ...... eated with nucleoside analogs.

@nl

type

label

Increased incidence of transfo ...... eated with nucleoside analogs.

@en

Increased incidence of transfo ...... eated with nucleoside analogs.

@nl

prefLabel

Increased incidence of transfo ...... eated with nucleoside analogs.

@en

Increased incidence of transfo ...... eated with nucleoside analogs.

@nl

P1433

Q43651033-378C5953-8E72-4B96-A7E9-45B0815FCDCF

P1476

Q43651033-32336B84-CA0A-47C1-B1B9-6DAE5216D6B4

P2093

Q43651033-0697D4F2-7047-4963-B1C9-5A13BD87737D

Q43651033-0F870AB6-BFD1-4F06-851D-082998211103

Q43651033-129CE825-F7DD-4A09-9337-8FCDD5B299BE

Q43651033-27CDD291-0635-4623-9D4A-C3DB9F54187E

Q43651033-3160B8D5-4A3C-44DC-8590-AC9C2D29D660

Q43651033-35FF70AC-DCD9-4F04-BC51-C522DAF623B8

Q43651033-441E0683-EF74-478E-B081-B43BB8292626

Q43651033-591A5EF0-74AC-42A7-A61E-F4659EE338F0

Q43651033-73971B4D-1DF5-49A4-8175-88DD2F4CA459

Q43651033-D52DC764-1BEC-4014-AB4E-5A42C3F9B1C2

P304

Q43651033-5233098B-CB70-40B4-AEB5-C06FB37520E4

P31

Q43651033-A72DA604-42BE-45FD-8036-D89C013BAFA1

P356

Q43651033-4149B4C4-0BDF-4EA5-9A4B-A0CF1CCC0ABD

P407

Q43651033-CA4E2678-E25D-4D06-8EAB-5D8A4096722B

P433

Q43651033-C4D198E2-3DBB-4E6C-BC6B-641F9B582355

P478

Q43651033-D5463BA1-A548-49DA-9023-D4ADD83F16A3

P50

Q43651033-9CA3D5A6-4239-4941-A0A5-9F2B3E2C18F6

Q43651033-DC8A766B-415D-400F-84D2-8198D9FB6C99

P577

Q43651033-879C020E-CECF-4C22-A09C-ED77AC7B1A36

P5875

Q43651033-FCEFB384-960D-4FBF-8DFB-4A92E94EC212

P698

Q43651033-8F2A16DA-10E2-4FA0-8F1C-8590E2099176

P921

Q43651033-195DD8A7-D918-499C-8E24-34F744475321

P356

JCO.2007.15.1530

P1433

Journal of Clinical Oncology

P1476

Increased incidence of transfo ...... eated with nucleoside analogs.

@en

P2093

Anne-Sophie Moreau

http://www.w3.org/2001/XMLSchema#string

Bryan T Ciccarelli

http://www.w3.org/2001/XMLSchema#string

Christopher J Patterson

http://www.w3.org/2001/XMLSchema#string

Evdoxia Hatjiharissi

http://www.w3.org/2001/XMLSchema#string

Irene M Ghobrial

http://www.w3.org/2001/XMLSchema#string

Jacob Soumerai

http://www.w3.org/2001/XMLSchema#string

Leukothea Ioakimidis

http://www.w3.org/2001/XMLSchema#string

Robert Manning

http://www.w3.org/2001/XMLSchema#string

Sophia Adamia

http://www.w3.org/2001/XMLSchema#string

Steven P Treon

http://www.w3.org/2001/XMLSchema#string

P304

250-255

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2007.15.1530

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

27

http://www.w3.org/2001/XMLSchema#string

P50

P577

2008-12-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23640367

http://www.w3.org/2001/XMLSchema#string

P698

19064987

http://www.w3.org/2001/XMLSchema#string

P921